Michel Lirette, MD | |
203 Turnpike Street, Suite 115, N Andover, MA 01845 | |
(978) 681-4505 | |
(978) 681-4507 |
Full Name | Michel Lirette |
---|---|
Gender | Male |
Speciality | Obstetrics & Gynecology |
Location | 203 Turnpike Street, N Andover, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598727117 | NPI | - | NPPES |
130002 | Other | HARVARD PILGRIM | |
3110541 | Other | MASS HEALTH | |
J13903 | Other | MA | BLUE SHIELD |
730461 | Other | MA | TUFTS HEALTH PLAN |
043429157 | Other | TAX ID | |
2008823 | Other | AETNA US HEALTHCARE | |
9784802 | Medicaid | MA | |
981320 | Other | NETWORK HEALTH CARE | |
0017405 | Other | NEIGHBORHOOD HEALTH PLAN | |
0100631Y0MA01 | Other | NH | BLUE SHIELD |
0700834 | Other | UNITED HEALTH CARE | |
730461 | Other | TUFTS | |
M17018 | Other | MA | BLUE SHIELD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 76941 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Michel Lirette, MD 203 Turnpike Street, Suite 115, North Andover, MA 01845 Ph: (978) 681-4505 | Michel Lirette, MD 203 Turnpike Street, Suite 115, N Andover, MA 01845 Ph: (978) 681-4505 |
News Archive
Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
Scientists from Israel have recently explored the effectiveness of two-dose and three-dose regimens of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine (Pfizer/BioNTech) to reduce viral load in breakthrough infections caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
A Florida State University research team, in coordination with a team from Japan, has found that the epithelial tissues that line the surfaces of organs throughout the body intrinsically have hot spots for cancerous tumors.
DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
› Verified 6 days ago